RxDoctor Payments Data

Syed Rizvi, MD

Family Medicine · Upland, CANPI 1669677365

Payments from drug & device makers

$1,763in general payments, 2019–2025

Across 90 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$240
  • Pfizer$162
  • Novartis$160
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$133
  • Amgen$132
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$102
  • plus $833 from 19 others

What the payments were for

  • Food & beverage$1,66895%
  • Education$955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,763 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$209,687
Medicare patients
317
Services billed
1,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$116,275
TrulicityDulaglutide66$75,891
JardianceEmpagliflozin67$72,198
OzempicSemaglutide55$57,701
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$45,678
XareltoRivaroxaban56$43,505
FarxigaDapagliflozin Propanediol48$43,413
Tresiba Flextouch U-200Insulin Degludec33$35,712
MyrbetriqMirabegron35$34,584
JanuviaSitagliptin Phosphate40$31,215
EntrestoSacubitril/Valsartan27$26,159
JanumetSitagliptin Phos/Metformin Hcl23$24,732
MounjaroTirzepatide16$20,303
ProliaDenosumab11$19,675
LinzessLinaclotide19$17,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$162$116,275178 claims
Lilly USA, LLCTrulicity, Mounjaro$67$96,19482 claims
Boehringer IngelheimJardiance, Spiriva Respimat$16$82,76986 claims
Novo NordiskOzempic$38$57,70155 claims
MerckJanuvia, Janumet$84$55,94763 claims
AstraZenecaFarxiga, Brilinta$56$54,49064 claims
Johnson & JohnsonXarelto, Invokana$75$50,95069 claims
Astellas Pharma US IncMyrbetriq$95$34,58435 claims
AbbVieLinzess, Savella, Synthroid$240$26,32074 claims
NovartisEntresto$160$26,15927 claims
AmgenProlia$132$19,67511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →